Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of MK-1439 versus efavirenz in treatment-naive adults with HIV-1 infection
2012-001573-93Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of doravirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Virologic response at Week 24 and Safety and tolerability through Week 24. Started Sep 2012; status: completed.
02
Drugs
doravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-001573-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001573-93.